Intravenous immunoglobulin (IVIg) ( DrugBank: IVIg )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
14	慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー	3
17	多系統萎縮症	1
164	眼皮膚白皮症	1
296	胆道閉鎖症	1

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

臨床試験数 : 175 / 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02414490 (ClinicalTrials.gov)	March 2015	13/3/2015	IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements	Intravenous Immunoglobulin (IVIg)Treatment-Related Fluctuations in Chronic Inflammatory Demyelinatin ...	Chronic Inflammatory Demyelinating Polyneuropathy	Drug: Intravenous Immunoglobulin	University of Minnesota	BriovaRx Infusion Services;CSL Behring	Completed	18 Years	85 Years	All	30		United States
2	NCT02372149 (ClinicalTrials.gov)	February 2015	12/2/2015	IVIg for Demyelination in Diabetes Mellitus	Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg)for Patients With Demyelination and Diab ...	Peripheral Neuropathy;Diabetes Mellitus;Chronic Inflammatory Demyelinating Polyneuropathy	Drug: 10% intravenous immunoglobulin (IVIg);Drug: 0.9% sodium chloride	University of Toronto	University Health Network, Toronto	Recruiting	18 Years	N/A	Both	25	Phase 4	Canada
3	NCT00001287 (ClinicalTrials.gov)	December 1990	3/11/1999	Intravenous Immunoglobulin (IVIg)for the Treatment of Chronic Inflammatory Demyelinating Polyneuropa ...	The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuro ...	Demyelinating Diseases;Paraproteinemias	Drug: intravenous immunoglobulin (IVIg)	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	60	Phase 2	United States

First Previous1Next Last

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00750867 (ClinicalTrials.gov)	June 2008	9/9/2008	Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins	Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins	Multiple System Atrophy	Drug: intravenous immunoglobulin (IVIg)	University of Massachusetts, Worcester	NULL	Completed	18 Years	N/A	All	9	Phase 2	United States

First Previous1Next Last

164. 眼皮膚白皮症

臨床試験数 : 15 / 薬物数 : 54 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00176865 (ClinicalTrials.gov)	August 2002	12/9/2005	Stem Cell Transplant for Immunologic or Histiocytic Disorders	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders ...	Hemophagocytic Lymphohistiocytosis;X-Linked Lymphoproliferative Disorders;Chediak-Higashi Syndrome;G ...	Procedure: Stem Cell Transplant;Drug: Fludarabine;Drug: Melphalan;Drug: Anti-thymocyte globulin (ATG ...	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	35 Years	All	19	Phase 2	United States

First Previous1Next Last

296. 胆道閉鎖症

臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01854827 (ClinicalTrials.gov)	October 2013	27/9/2012	Safety Study of Intravenous Immunoglobulin (IVIG)Post-Portoenterostomy in Infants With Biliary Atres ...	A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG)Therapy Following Portoenterostomy in Infants ...	Biliary Atresia	Drug: Intravenous immunoglobulin (IVIG)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	N/A	120 Days	All	30	Phase 1/Phase 2	United States;Canada

First Previous1Next Last

先頭へ